Cargando…

Commentary: A GSH/CB dual-controlled self-assembled nanomedicine for high-efficacy doxorubicin-resistant breast cancer therapy

Detalles Bibliográficos
Autor principal:	Tian, Tian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9744131/ https://www.ncbi.nlm.nih.gov/pubmed/36518660 http://dx.doi.org/10.3389/fphar.2022.1081912

Ejemplares similares

A GSH/CB Dual-Controlled Self-Assembled Nanomedicine for High-Efficacy Doxorubicin-Resistant Breast Cancer Therapy
por: Yang, Yang, et al.
Publicado: (2022)

Cannabigerol Action at Cannabinoid CB(1) and CB(2) Receptors and at CB(1)–CB(2) Heteroreceptor Complexes
por: Navarro, Gemma, et al.
Publicado: (2018)

GSH rescue by N-acetylcysteine
por: Ruffmann, R., et al.
Publicado: (1991)

Nanomedicine-Mediated Therapies to Target Breast Cancer Stem Cells
por: He, Lili, et al.
Publicado: (2016)

Commentary: Astroglial CB(1) Receptors Determine Synaptic D-Serine Availability to Enable Recognition Memory
por: Guo, Yan-Chen, et al.
Publicado: (2018)

The Alleviation of LPS-Induced Murine Acute Lung Injury by GSH-Mediated PEGylated Artesunate Prodrugs
por: Hao, Dan-Li, et al.
Publicado: (2022)

System X(c) (−)/GSH/GPX4 axis: An important antioxidant system for the ferroptosis in drug-resistant solid tumor therapy
por: Li, Feng-Jiao, et al.
Publicado: (2022)

The potential role of nanomedicine in the treatment of breast cancer to overcome the obstacles of current therapies
por: Yang, Fan, et al.
Publicado: (2023)

Ferroptosis-Inducing Nanomedicine for Cancer Therapy
por: Wang, Yang, et al.
Publicado: (2021)

A multifunctional oxidative stress nanoamplifier with ROS amplification and GSH exhaustion for enhanced chemodynamic therapy
por: Zhong, Wenzhao, et al.
Publicado: (2022)

Editorial: Women in nanomedicine
por: Chuah, Lay-Hong, et al.
Publicado: (2023)

Functional Nanomedicines for Targeted Therapy of Bladder Cancer
por: Tang, Chao, et al.
Publicado: (2021)

Discovery of Novel Doxorubicin Metabolites in MCF7 Doxorubicin-Resistant Cells
por: Wang, Xu, et al.
Publicado: (2019)

Cannabinoids Modulate Neuronal Activity and Cancer by CB1 and CB2 Receptor-Independent Mechanisms
por: Soderstrom, Ken, et al.
Publicado: (2017)

Dual-Targeted Self-Assembled DNA Hydrogels Decorated With Multivalent Aptamers Loaded With DOX for Anticancer Therapy
por: Jin, Fangfang, et al.
Publicado: (2022)

Mesenchymal Stem Cell–Derived Exosomes: A Promising Biological Tool in Nanomedicine
por: Wei, Wumei, et al.
Publicado: (2021)

Editorial: Advances and Challenges in Nanomedicine
por: Hua, Susan, et al.
Publicado: (2018)

Activation of cancer immunotherapy by nanomedicine
por: Wang, Lijuan, et al.
Publicado: (2022)

Corrigendum: Discovery of Novel Doxorubicin Metabolites in MCF7 Doxorubicin-Resistant Cells
por: Wang, Xu, et al.
Publicado: (2020)

Acetaldehyde-modified-cystine functionalized Zr-MOFs for pH/GSH dual-responsive drug delivery and selective visualization of GSH in living cells
por: Lin, Caixue, et al.
Publicado: (2020)

Pharmacologic therapies of ARDS: From natural herb to nanomedicine
por: Meng, Linlin, et al.
Publicado: (2022)

Cannabinoid CB1 and CB2 Receptor-Mediated Arrestin Translocation: Species, Subtype, and Agonist-Dependence
por: Ibsen, Mikkel Søes, et al.
Publicado: (2019)

A Novel Agent Enhances the Chemotherapeutic Efficacy of Doxorubicin in MCF-7 Breast Cancer Cells
por: Wang, Liang, et al.
Publicado: (2016)

Therapeutic polymeric nanomedicine: GSH-responsive release promotes drug release for cancer synergistic chemotherapy
por: Shen, Jie, et al.
Publicado: (2019)

ABCG2 is not able to catalyze glutathione efflux and does not contribute to GSH-dependent collateral sensitivity
por: Gauthier, Charlotte, et al.
Publicado: (2013)

High Expression of G6PD Increases Doxorubicin Resistance in Triple Negative Breast Cancer Cells by Maintaining GSH Level
por: Luo, Man, et al.
Publicado: (2022)

Selective Estrogen Receptor Modulators: Cannabinoid Receptor Inverse Agonists with Differential CB1 and CB2 Selectivity
por: Franks, Lirit N., et al.
Publicado: (2016)

N-linoleyltyrosine resisted the growth of non-small cell lung cancer cells via the regulation of CB(1) and CB(2) involvement of PI3K and ERK pathways
por: Hu, Yan, et al.
Publicado: (2023)

Application Perspectives of Nanomedicine in Cancer Treatment
por: Hou, Shanshan, et al.
Publicado: (2022)

Editorial: Advances on targeted nanomedicines for atherosclerosis
por: Han, Qinggong, et al.
Publicado: (2022)

Supramolecular Nanomedicines of In-Situ Self-Assembling Peptides
por: Zhang, Ying, et al.
Publicado: (2022)

Voltage dependence of the cannabinoid CB1 receptor
por: Goldberger, Esty, et al.
Publicado: (2022)

GSH-sensitive polymeric prodrug: Synthesis and loading with photosensitizers as nanoscale chemo-photodynamic anti-cancer nanomedicine
por: Luo, Lei, et al.
Publicado: (2022)

Intracellular Reduction-Responsive Molecular Targeted Nanomedicine for Hepatocellular Carcinoma Therapy
por: Ding, Lei, et al.
Publicado: (2022)

L-GSH Supplementation in Conjunction With Rifampicin Augments the Treatment Response to Mycobacterium tuberculosis in a Diabetic Mouse Model
por: Beever, Abrianna, et al.
Publicado: (2022)

Macrophage-targeted nanomedicine for the diagnosis and management of atherosclerosis
por: Hu, Ping Ping, et al.
Publicado: (2022)

Editorial: Translating nanomedicines for anti-cancer treatment
por: Siram, Karthik, et al.
Publicado: (2023)

Candidate Therapeutics by Screening for Multitargeting Ligands: Combining the CB2 Receptor With CB1, PPARγ and 5-HT4 Receptors
por: El-Atawneh, Shayma, et al.
Publicado: (2022)

Expression and Functions of the CB(2) Receptor in Human Leukocytes
por: Simard, Mélissa, et al.
Publicado: (2022)

Editorial: Therapeutic potential of the cannabinoid CB2 receptor
por: Smoum, Reem, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_674le5u1a4j5o4b52mn5amvd6q